
|Peer-Reviewed|December 23, 2020
- January 2021
- Volume 27
- Issue 1
Supplemental Material: Clinical and Economic Burden of Intravenous Paclitaxel or nab-Paclitaxel for Metastatic Breast Cancer
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Advertisement
Articles in this issue
almost 5 years ago
ASH 2020: Clinical Updatesalmost 5 years ago
ASH 2020: COVID-19 and Hematologyalmost 5 years ago
ASH 2020: CAR T-Cell Therapy Updatesalmost 5 years ago
ASH 2020: The Next Wavealmost 5 years ago
2020 SABCS: Topics in Precision OncologyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
2
Most Americans Pleased With Health Insurance Options for 2026
3
Medicaid Expansion Associated With Lower Mortality in NSCLC
4
Diabetes Tied to Increased Risk of Sudden Cardiac Death
5












































